CRISPR Therapeutics AG operates in the healthcare sector, within the biotechnology industry focused on gene-editing and genome-based therapies. The company develops treatments based on CRISPR-Cas9 technology, aimed at modifying DNA to address complex diseases.

Its main areas of activity include:

• Development of gene therapies using CRISPR-Cas9 technology.
• Clinical programs targeting blood disorders and rare diseases.
• Research in oncology, immunotherapy and metabolic conditions.
• Biotechnology platforms for genome-editing innovation.

The company’s portfolio consists of therapies in clinical development, using both ex vivo and in vivo gene-editing approaches to treat conditions such as sickle cell disease and other genetic disorders.

CRISPR Therapeutics operates internationally, with a primary presence in the United States and Europe. Its structure includes research centers, clinical-development teams, regulatory units and partnerships with pharmaceutical companies and academic institutions.

Industry dynamics affecting the company include regulatory frameworks for advanced therapies, competition within the biotechnology sector, high R&D costs, clinical trial outcomes and the growing demand for precision medicine.

Shares of CRISPR Therapeutics AG trade on the Nasdaq under the ticker CRSP.

History and Development

CRISPR Therapeutics was founded in 2013 in Switzerland with the objective of translating CRISPR-Cas9 gene-editing technology into therapeutic applications.

In its early years, the company focused on validating its scientific platform, building intellectual property and establishing a pipeline of potential treatments. Initial progress included preclinical research and the development of early-stage therapeutic programs targeting genetic diseases.

As the company evolved, it expanded its clinical pipeline and formed strategic partnerships with global pharmaceutical companies to support development and commercialization efforts. In 2016, CRISPR Therapeutics completed its initial public offering (IPO) on the Nasdaq, securing funding to advance its clinical programs and expand research capabilities.

In recent years, the company has advanced multiple therapies into clinical trials, particularly in hematology and oncology, while refining its gene-editing technologies.